NDASUBCUTANEOUSSOLUTIONPriority Review
Approved
Dec 2022
Lifecycle
Peak
Competitive Pressure
0/100
Data completeness
3/8 — Basic
Priority Review
Drug data last refreshed 21h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SUNLENCA (lenacapavir sodium) is a first-in-class HIV capsid inhibitor administered as a subcutaneous injection for treatment-experienced adults with HIV-1. It represents a novel mechanism targeting viral capsid stability and has demonstrated potent antiviral activity in clinical trials. This small-molecule therapy offers a new option for patients with limited alternatives due to resistance or tolerability concerns.
Peak14.9 years to LOE
SUNLENCA is in peak commercial phase post-launch with growing adoption among HIV specialists; commercial teams are expanding to build market penetration in a niche but strategic indication.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Why This Matters for Your Career
Gilead Sciences is hiring 1 role related to this product
Worked on SUNLENCA at Gilead Sciences? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.